Hidden value of colon capsule endoscopy: balancing patient preference, environmental impact, and cost-effectiveness
Endoscopy · 01.12.2025 · 57 (12) · 1425-1426
DOI: 10.1055/a-2712-6852 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.12.2025. Verfasst von Anastasios Koulaouzidis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Letter to: Cost-effectiveness of colon capsule endoscopy in colorectal cancer screening: a modeling study Endoscopy 2025; 57(10): 1095-1105 DOI: 10.1055/a-2658-0960 10.1055/a-2658-0960 We read with interest the modeling study by de Jonge et al. evaluating the cost-effectiveness of colon capsule endoscopy (CCE) in colorectal cancer screening [ 1 ]. Using the MISCAN-Colon model, the authors concluded that CCE strategies are dominated by biennial fecal immunochemical test (FIT) and 10-yearly colonoscopy, largely due to high CCE unit costs (€600) and similar long-term outcomes to FIT. Although the conclusion supports the modeling assumptions and is in line with previous studies [ 2 ], we caution against overgeneralizing to all settings. The threshold analysis showed that CCE could be cost-effective at lower costs (e.g. €425 for biennial screening; prices are declining). Adherence assumptions are also critical. The sensitivity analyses assumed 25%–75% uptake, but recent trials show stronger patient preference for CCE over colonoscopy (45.8% vs. 11.4%) [ 3 ], with acceptability rivaling or exceeding FIT due to its non-invasive nature and potential reach of underserved communities. If CCE achieved FIT-like adherence (~75%) rather than colonoscopy-like adherence (~25%), it could yield substantially greater population-level benefits. Importantly, the model treats adherence as a static probability, yet real-world uptake is heterogeneous. Studies from Pioche et al. suggest CCE uptake is not a simple substitution for FIT or colonoscopy [ 4 ]; it may uniquely appeal to niche groups who decline colonoscopy for sociocultural reasons [ 5 ]. Explicitly segmenting FIT acceptors, FIT refusers who accept CCE, and colonoscopy acceptors/refusers would allow more realistic modeling of the incremental reach of CCE. The choice of a fixed willingness-to-pay threshold of €20 000 per quality-adjusted life year (QALY) gained may also be overly conservative. In the UK, National Institute for Health and Care Excellence considers values between £20 000 and £30 000 per additional QALY gained to represent good value for money [ 6 ]. Additionally, CCE has a role in capacity-constrained settings or for individuals who decline colonoscopy. Moreover, there is an environmental impact: the eCO 2 value per patient of CCE is half that of colonoscopy, at 2.9 vs. 5.6 kg [ 7 ]. Artificial intelligence-driven efficiencies with extended post-negative surveillance intervals (5–10 years rather than the modeled 2–3 years), together with patient preferences and environmental benefits, may yet prove CCE to be a cost-effective modality within colorectal cancer screening programs. Publication History Article published online: 27 November 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Autor:innen und Institutionen
- Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Surgery, Odense University Hospital, Odense, Denmark.
- Warwick Medical School, University of Warwick, Coventry, United Kingdom of Great Britain and Northern Ireland.
- Institute of Precision Diagnostics and Translational Medicine, University Hospital of Coventry and Warwickshire, Coventry, United Kingdom of Great Britain and Northern Ireland.
- Department of Gastroenterology, Skåne University Hospital, Malmö, Sweden.
ORCID-Profile: Anastasios Koulaouzidis, Ervin Toth
Zitieren
APA
Koulaouzidis, A., Lei, I. I., Toth, E., Marlicz, W., & Arasaradnam, R. P. (2025). Hidden value of colon capsule endoscopy: balancing patient preference, environmental impact, and cost-effectiveness. Endoscopy, 57(12), 1425-1426. https://doi.org/10.1055/a-2712-6852
Vancouver
Koulaouzidis A, Lei II, Toth E, Marlicz W, Arasaradnam RP. Hidden value of colon capsule endoscopy: balancing patient preference, environmental impact, and cost-effectiveness. Endoscopy. 2025;57(12):1425-1426. doi:10.1055/a-2712-6852
BibTeX
@article{Koulaouzidis2025,
author = {Koulaouzidis, Anastasios and Lei, Ian I and Toth, Ervin and Marlicz, Wojciech and Arasaradnam, Ramesh P},
title = {Hidden value of colon capsule endoscopy: balancing patient preference, environmental impact, and cost-effectiveness},
journal = {Endoscopy},
year = {2025},
volume = {57},
number = {12},
pages = {1425--1426},
doi = {10.1055/a-2712-6852}
}
EUVIMED